var data={"title":"Amoxicillin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amoxicillin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5631?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amoxicillin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amoxicillin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amoxicillin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134511\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Moxatag</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134512\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Novamoxin;</li>\n      <li>Pro-Amox-250;</li>\n      <li>Pro-Amox-500</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134562\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134516\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Unless otherwise specified, all dosing recommendations based on immediate release product formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild or moderate infection: 250 mg every 8 hours or 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild or moderate infection (lower respiratory tract): 500 mg every 8 hours or 875 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe infection (as step-down therapy): 500 mg every 8 hours or 875 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release: 775 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax, inhalational postexposure prophylaxis (CDC recommendations) (off-label use):</b> Oral: 1,000 mg every 8 hours (Hendricks [CDC 2014]). <b>Note:</b> Use <b>only</b> if isolates of the specific <i>B. anthracis</i> are sensitive to amoxicillin (MIC &le;0.125 mcg/mL); may be administered to pregnant and breast-feeding women. Duration of antibiotic postexposure prophylaxis (PEP) is 60 days whether a patient is vaccinated, partially vaccinated, or unvaccinated (Hendricks [CDC 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ear, nose, throat, genitourinary tract, or skin/skin structure infections: </b> <b>Note:</b> IDSA guidelines recommend amoxicillin-clavulanate as preferred first-line treatment of acute bacterial rhinosinusitis (ABRS) (IDSA [Chow 2012]); AAO-HNS guidelines for adult sinusitis recommend either amoxicillin or amoxicillin-clavulanate as initial first-line therapy of ABRS, with consideration given for amoxicillin-clavulanate instead of amoxicillin in certain patients (eg, moderate to severe ABRS symptoms, antibiotic use in past month, high prevalence of resistant bacteria in community, history of recurrent ABRS, presence of comorbidities) (AAO-HNS [Rosenfeld 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mild-to-moderate:</i> Oral: 500 mg every 12 hours <b>or</b> 250 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe:</i> Oral: 875 mg every 12 hours <b>or</b> 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tonsillitis and/or pharyngitis:</i> Oral: Extended release: 775 mg once daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, prophylaxis (off-label use):</b> Oral: 2 g 30 to 60 minutes before procedure. <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in who underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Erysipeloid (off-label use):</b> Oral: 500 mg 3 times daily for 7 to 10 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Helicobacter pylori </b></i>\n      <b>eradication:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">American College of Gastroenterology guidelines (Chey 2007; Chey 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Clarithromycin triple therapy</i>: 1,000 mg twice daily in combination with clarithromycin 500 mg twice daily plus a standard-dose or double-dose proton pump inhibitor; continue regimen for 14 days. <b>Note:</b> Avoid use of clarithromycin triple therapy in patients with risk factors for macrolide resistance (eg, prior macrolide exposure, local clarithromycin resistance rates &ge;15%, eradication rates with clarithromycin-based regimens &le;85%) (ACG [Chey 2017]; Fallone 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Concomitant regimen</i>: 1,000 mg twice daily in combination with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily, plus a standard-dose proton pump inhibitor twice daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Sequential regimen</i>: 1,000 mg twice daily plus a standard-dose proton pump inhibitor twice daily for 5 to 7 days; then follow with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily, and a standard-dose proton pump inhibitor twice daily for 5 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hybrid regimen</i>: 1,000 mg twice daily plus a standard-dose proton pump inhibitor twice daily for 7 days; then follow with amoxicillin 1,000 mg twice daily, clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily, and a standard-dose proton pump inhibitor twice daily for 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Levofloxacin triple regimen</i>: 1,000 mg twice daily in combination with a standard-dose proton pump inhibitor twice daily and levofloxacin 500 mg once daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower respiratory tract infections:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> 875 mg every 12 hours <b>or </b>500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing: </i>Pneumonia, community-acquired: Outpatient empiric therapy: 1,000 mg 3 times daily for a minimum of 5 days (patients should be afebrile for &ge;48 hours and clinically stable before discontinuation of therapy); use in combination with a macrolide (preferred) or doxycycline (Mandell 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (excluding neurologic disease) (off-label use) (IDSA [Wormser 2006]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acrodermatitis chronica atrophicans:</i> 500 mg 3 times daily for 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Erythema migrans:</i> 500 mg 3 times daily for 14 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lyme arthritis:</i> 500 mg 3 times daily for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lyme carditis (mild):</i> 500 mg 3 times daily for 14 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme neuroborreliosis (off-label use) (when doxycycline is contraindicated): </b>Oral: 500 mg 3 times daily for 14 to 21 days. <b>Note:</b> Oral regimens should be reserved for patients with cranial nerve palsy without evidence of meningitis (IDSA [Wormser 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Periodontitis (aggressive) (in combination with metronidazole) associated with presence of </b> <b><i>Actinobacillus actinomycetemcomitans </i></b> <b>(AA) (off-label use):</b> Oral: 500 mg every 8 hours for 10 days used in addition to scaling and root planing (Varela 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis, group A streptococci:</b> Oral: 1,000 mg once daily or 500 mg twice daily (maximum: 1,000 mg/day) for 10 days (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia (off-label use):</b> Oral: 2 g 1 hour prior to procedure (ADA/AAOS 2003). <b>Note:</b> In general, patients with prosthetic joint implants do not require prophylactic antibiotics prior to dental procedures. In planning an invasive oral procedure, dental consultation with the patient's orthopedic surgeon may be advised to review the risks of infection (Sollecito 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection, chronic antimicrobial suppression of prosthetic joint infection associated with beta-hemolytic streptococci, penicillin-susceptible <b><i>Enterococcus</i></b> spp, or <i>Cutibacterium</i> spp (off-label use):</b> Oral: 500 mg 3 times daily (Osmon 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134538\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amoxicillin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Unless otherwise specified, all pediatric dosing recommendations based on immediate release product formulations (oral suspension, chewable tablet, tablet, and capsule).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Mild to moderate infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &le;3 months: Oral: 25 to 50 mg/kg/day in divided doses every 8 hours (<i>Red Book</i> [AAP 2015]). <b>Note:</b> Manufacturer's labeling recommends a maximum daily dose of 30 mg/kg/<b>day</b> divided into 2 doses per day for this age group.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &gt;3 months, Children, and Adolescents (&lt;40 kg):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AAP recommendations (<i>Red Book</i> [AAP 2015]): Oral: 25 to 50 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Oral: 20 to 40 mg/kg/day in divided doses every 8 hours (maximum dose: 500 mg/dose) <b>or</b> 25 to 45 mg/kg/day in divided doses every 12 hours (maximum dose: 875 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children, and Adolescents (&ge;40 kg): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Severe infection (as step-down therapy):</b> Infants, Children, and Adolescents: Oral: 80 to 100 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg/dose for most indications (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anthrax (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cutaneous, without systemic involvement: Children and Adolescents: Oral: 75 mg/kg/day in 3 divided doses. Maximum dose: 1,000 mg/dose. Duration of therapy: 7 to 10 days for naturally acquired infection, up to 60 days for biological weapon-related exposure (AAP [Bradley 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inhalational, postexposure prophylaxis: Children and Adolescents: Oral: 75 mg/kg/day in divided doses every 8 hours for 60 days after exposure; maximum dose: 1,000 mg/dose (AAP [Bradley 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis), exit-site or tunnel infection (off-label use):</b> Infants, Children, and Adolescents: Oral: 10 to 20 mg/kg once daily; maximum dose: 1,000 mg/dose (Warady [ISPD 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, prophylaxis (off-label use):</b> Infants, Children, and Adolescents: Oral: 50 mg/kg 1 hour before procedure (maximum dose: 2,000 mg/dose) (Wilson 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Helicobacter pylori</i></b>\n      <b> eradication:</b> Children and Adolescents: Oral: 50 mg/kg/day in 2 divided doses for 10 to 14 days; maximum daily dose: 2,000 mg/<b>day</b>. Administer in combination with a proton pump inhibitor or bismuth subsalicylate and at least one other antibiotic (clarithromycin and/or metronidazole) (NASPGHAN/ESPGHAN [Koletzko 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme disease (off-label use):</b> Infants, Children, and Adolescents: Oral: 50 mg/kg/day divided every 8 hours (maximum dose: 500 mg/dose) (Halperin 2007; Wormser 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute:</b> Infants &ge;2 months and Children: Oral: 80 to 90 mg/kg/day divided every 12 hours; variable duration of therapy, if &lt;2 years of age or severe symptoms (any age): 10-day course; if 2 to 5 years of age with mild to moderate symptoms: 7-day course; &ge;6 years of age with mild to moderate symptoms: 5- to 7-day course; some experts recommend initiating with 90 mg/kg/day (AAP [Lieberthal 2013]; <i>Red Book</i> [AAP 2015]); a maximum dose is not provided in the Guidelines for The Diagnosis and Management of Acute Otitis Media (AAP [Lieberthal 2013]); however, some experts suggest a maximum daily dose of 4,000 mg/day for high-dose amoxicillin therapy (Bradley 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis, prophylaxis (for patients receiving peritoneal dialysis who require dental procedures) (off-label use):</b> Infants, Children, and Adolescents: Oral: 50 mg/kg administered 30 to 60 minutes before dental procedure (maximum dose: 2000 mg/dose) (Warady [ISPD 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumococcal infection prophylaxis for anatomic or functional asplenia (eg, sickle cell disease ([SCD]) (off-label use) (Price 2007; <i>Red Book </i>[AAP 2015]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants (&lt;2 months to 1 year, or as soon as SCD is diagnosed or asplenia occurs) and Children &le;5 years: Oral: 20 mg/kg/day in divided doses every 12 hours (maximum dose: 250 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years and Adolescents: Oral: 250 mg every 12 hours. <b>Note:</b> The decision to discontinue penicillin prophylaxis after 5 years of age in children who have not experienced invasive pneumococcal infection and have received recommended pneumococcal immunizations is patient and clinician dependent.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired (CAP) (Bradley [IDSA 2011]):</b> Infants &ge;3 months, Children, and Adolescents: <b>Note:</b> In pediatric patients 5 to 15 years of age, a macrolide antibiotic may be a more reasonable first choice as <i>M. pneumoniae</i> is the chief cause of pneumonia in this age group.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Empiric treatment: Oral: 90 mg/kg/day in divided doses every 12 hours (maximum daily dose: 4,000 mg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Group A <i>Streptococcus</i>: Oral: 50 to 75 mg/kg/day in divided doses every 12 hours (maximum daily dose: 4,000 mg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>H. influenzae</i>: Oral: 75 to 100 mg/kg/day in divided doses every 8 hours (maximum daily dose: 4,000 mg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. pneumoniae</i> (MICs to penicillin &le;2 mcg/mL), mild infection or step-down therapy: Oral: 90 mg/kg/day in divided doses every 12 hours <b>or</b> 45 mg/kg/day in divided doses every 8 hours (maximum daily dose: 4,000 mg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinosinusitis, acute bacterial; uncomplicated:</b> <b>Note:</b> AAP guidelines recommend amoxicillin as first-line empiric therapy for pediatric patients 1 to 18 years with uncomplicated cases and where resistance is not suspected; however, the IDSA guidelines consider amoxicillin/clavulanate as the preferred therapy (Chow 2012, Wald 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low dose: Oral: 45 mg/kg/day in divided doses every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High dose (use reserved for select patients; see <b>Note</b>): Oral: 80 to 90 mg/kg/day in divided doses every 12 hours (maximum dose: 1,000 mg/dose). <b>Note:</b> Should only be used in the following: Mild to moderate infections in communities with a high prevalence of nonsusceptible <i>S. pneumoniae</i> resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tonsillopharyngitis; Group A streptococcal infection, treatment and primary prevention of rheumatic fever:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Children &ge;3 years and Adolescents: Oral: 50 mg/kg once daily <b>or</b> 25 mg/kg twice daily for 10 days; maximum daily dose: 1,000 mg/<b>day</b> (Gerber 2009; Shulman 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Children &ge;12 years and Adolescents: Oral: 775 mg once daily for 10 days. <b>Note:</b> Patient must be able to swallow tablet whole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection, prophylaxis (hydronephrosis, vesicoureteral reflux):</b> Infants &le;2 months: Oral: 10 to 15 mg/kg once daily; some suggest administration in the evening (drug resides in bladder longer); <b>Note:</b> Due to resistance, amoxicillin should not be used for prophylaxis after 2 months of age (Belarmino 2006; Greenbaum 2006; Mattoo 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134517\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134518\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release: <b>Note:</b> Avoid immediate-release 875 mg tablet in patients with GFR &lt;30 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 30 mL/minute: 250 to 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute: 250 to 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 250 to 500 mg every 24 hours; administer after dialysis on dialysis days (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the following recommendations have been used by some clinicians (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate infection: Dosing based on 25 to 50 mg/kg/day divided every 8 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 8 to 20 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 8 to 20 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 8 to 20 mg/kg/dose every 24 hours; give after dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Peritoneal dialysis: 8 to 20 mg/kg/dose every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe infection (high dose): Dosing based on 80 to 90 mg/kg/day divided every 12 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 20 mg/kg/dose every 12 hours; do not use the 875 mg tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 20 mg/kg/dose every 24 hours; do not use the 875 mg tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 20 mg/kg/dose every 24 hours; give after dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Peritoneal dialysis: 20 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release: Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673165\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134488\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (80 mL, 100 mL, 150 mL); 200 mg/5 mL (50 mL, 75 mL, 100 mL); 250 mg/5 mL (80 mL, 100 mL, 150 mL); 400 mg/5 mL (50 mL, 75 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 875 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moxatag: 775 mg [contains cremophor el, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 775 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134472\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50665095\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the United States. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Novamoxin: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension Reconstituted, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Novamoxin: 125 mg/5 mL (75 mL, 100 mL, 150 mL); 250 mg/5 mL (75 mL, 100 mL, 150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet Chewable, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Novamoxin: 125 mg, 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134492\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer around-the-clock to promote less variation in peak and trough serum levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Administer within 1 hour of finishing a meal; do not chew or crush tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension: Shake well before use; may be mixed with formula, milk, fruit juice, water, ginger ale, or cold drinks; administer dose immediately after mixing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134491\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ear, nose, and throat infections (pharyngitis/tonsillitis, otitis media, rhinosinusitis):</b> Immediate-release: Treatment of infections due to beta-lactamase-negative <i>Streptococcus</i> spp (alpha- and beta-hemolytic isolates only), <i>Streptococcus pneumoniae</i>, <i>Staphylococcus</i> spp., or <i>Haemophilus influenzae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Genitourinary tract infections:</b> Immediate-release: Treatment of infections of the genitourinary tract due to beta-lactamase-negative <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, or <i>Enterococcus faecalis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <b>\n          <i>Helicobacter pylori</i></b>\n        <b>eradication</b>:</b> Immediate-release: Eradication of <i>H. pylori</i> to reduce the risk of duodenal ulcer recurrence as a component of combination therapy in patients with active or 1 year history of duodenal ulcer disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower respiratory tract infections (including pneumonia):</b> Immediate-release: Treatment of infections of the lower respiratory tract due to beta-lactamase-negative <i>Streptococcus</i> spp. (alpha- and beta-hemolytic strains only), <i>Streptococcus pneumoniae</i>, <i>Staphylococcus</i> spp., or <i>H. influenzae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis and tonsillitis:</b> Extended-release: Treatment of tonsillitis and/or pharyngitis due to <i>Streptococcus pyogenes</i> in adults and pediatric patients &ge;12 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Immediate-release: Treatment of infections of the skin and skin structure due to beta-lactamase-negative <i>Streptococcus</i> spp. (alpha- and beta-hemolytic strains only), <i>Staphylococcus</i> spp., or <i>E. coli</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475041\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Anthrax, inhalational post-exposure prophylaxis (documented susceptible organisms) (adults); Anthrax, inhalational post-exposure prophylaxis (documented susceptible organisms) (children); Community-acquired pneumonia (children); Erysipeloid; Group A streptococcal pharyngitis (children); Infective endocarditis (prophylaxis); Lyme disease (excluding neurologic disease); Lyme neuroborreliosis; Prophylaxis in patients with prosthetic joint implants undergoing dental procedures which produce bacteremia; Prosthetic joint infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134569\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Amoxicillin may be confused with amoxapine, Augmentin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Amoxil may be confused with amoxapine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fisamox [Australia] may be confused with Fosamax brand name for alendronate [US, Canada, and multiple international markets] and Vigamox brand name for moxifloxacin [US, Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Limoxin [Mexico] may be confused with Lanoxin brand name for digoxin [US, Canada, and multiple international markets]; Lincocin brand name for lincomycin [US, Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zimox: Brand name for amoxicillin [Italy], but also the brand name for carbidopa/levodopa [Greece]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zimox [Italy] may be confused with Diamox which is the brand name for acetazolamide [Canada and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134479\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Hypersensitivity angiitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, anxiety, behavioral changes, confusion, dizziness, headache, hyperactivity (reversible), insomnia, seizure </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Acute generalized exanthematous pustulosis, erythematous maculopapular rash, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Dental discoloration (brown, yellow, or gray; rare), diarrhea, hemorrhagic colitis, melanoglossia, mucocutaneous candidiasis, nausea, pseudomembranous colitis, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Crystalluria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, eosinophilia, hemolytic anemia, leukopenia,thrombocytopenia, thrombocytopenia purpura </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholestatic hepatitis, cholestatic jaundice, hepatitis (acute cytolytic), increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: Serum sickness-like reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134495\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious hypersensitivity to amoxicillin (eg, anaphylaxis, Stevens-Johnson syndrome) or to other beta-lactams, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Infectious mononucleosis (suspected or confirmed)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134476\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, including amoxicillin, especially with a history of beta-lactam hypersensitivity (including severe reactions with cephalosporins) and/or a history of sensitivity to multiple allergens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infectious mononucleosis: A high percentage of patients with infectious mononucleosis develop an erythematous rash during amoxicillin therapy; avoid use in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended in patients with GFR &lt;30 mL/minute. Avoid extended release 775 mg tablet and immediate release 875 mg tablet in patients with GFR &lt;30 mL/minute or patients requiring hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chewable tablets: May contain phenylalanine; see manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298741\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134481\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8673&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134484\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5720643\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Amoxicillin crosses the placenta (Muller 2009). Maternal use of amoxicillin has generally not resulted in an increased risk of adverse fetal effects; however, a possible association with cleft lip with cleft palate has been observed in some studies (more data is needed) (Lin 2012; Puh&oacute; 2007). Amoxicillin may be used for the management of <i>Bacillus anthracis </i>in pregnant women when penicillin susceptibility is documented (Meaney-Delman 2014). Amoxicillin is an alternative antibiotic for the treatment of chlamydial infections in pregnancy (CDC [Workowski 2015]). Amoxicillin can also be used in the management of preterm premature rupture of membranes and in certain situations prior to vaginal delivery in women at high risk for endocarditis (ACOG 120 2011; ACOG 139 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of amoxicillin may be altered (Andrew 2007). Oral ampicillin-class antibiotics are poorly absorbed during labor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5695240\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Amoxicillin is excreted in breast milk (Kafetzis 1981).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of amoxicillin is 0.15% to 0.54% when calculated using the highest average breast milk concentration located and compared to an infant therapeutic dose of 25 to 90 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using the highest average milk concentration (0.9 mcg/mL), the estimated daily infant dose via breast milk is 0.135 mg/kg/day. This milk concentration was obtained following maternal administration of a single oral dose of amoxicillin 1,000 mg (Kafetzis 1981).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Self-limiting diarrhea, rash, and somnolence have been reported in nursing infants exposed to amoxicillin (Benyamini 2005; Goldstein 2009; Ito 1993); the manufacturer warns of the potential for allergic sensitization in the infant. In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Although the manufacturer recommends that caution be exercised when administering amoxicillin to breastfeeding women, amoxicillin is considered compatible with breastfeeding when used in usual recommended doses (WHO 2002). Amoxicillin has been recommended to treat mastitis in breastfeeding women when penicillin susceptibility is documented (WHO 2000) and also for the management of <i>Bacillus anthracis </i>(Meaney-Delman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134498\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134486\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; assess patient at beginning and throughout therapy for infection; monitor for signs of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134475\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134494\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Immediate-release: Rapid with or without food</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release: Rate of absorption is slower compared to immediate-release formulations; food decreases the rate but not extent of absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Readily into liver, lungs, prostate, muscle, middle ear effusions, maxillary sinus secretions, bone, gallbladder, bile, and into ascitic and synovial fluids; poor CSF penetration (except when meninges are inflamed)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Adults: Immediate-release: 61.3 minutes; Extended-release: 90 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Capsule, oral suspension: 1 to 2 hours; Chewable tablet: 1 hour; Extended-release: 3.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (60% as unchanged drug) lower in neonates</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134497\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Amoxicillin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $24.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (500): $190.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Amoxicillin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $33.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $67.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Amoxicillin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (100 mL): $3.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (75 mL): $6.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (100 mL): $6.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/5 mL (75 mL): $7.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Moxatag Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">775 mg (10): $188.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Amoxicillin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $49.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">875 mg (100): $87.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134499\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A.M. Mox (TH);</li>\n      <li>Abiolex (CL);</li>\n      <li>Acilina (PY);</li>\n      <li>Acimox (MX);</li>\n      <li>Adbiotin (CO);</li>\n      <li>Alfamox (IT);</li>\n      <li>Almacin (HR);</li>\n      <li>Almorsan (AR);</li>\n      <li>Alphamox (AU);</li>\n      <li>Amicil (MX);</li>\n      <li>Amimox (SE);</li>\n      <li>Amitron (ES);</li>\n      <li>Amixen (AR);</li>\n      <li>Amixozan (DK);</li>\n      <li>Ammimox (TH);</li>\n      <li>Amobay (MX);</li>\n      <li>Amobiotic (CL);</li>\n      <li>Amoclan (JO, SA);</li>\n      <li>Amodex (FR);</li>\n      <li>Amoksilav (TR);</li>\n      <li>Amoksyl (UA);</li>\n      <li>Amolin (JP);</li>\n      <li>Amorion (FI);</li>\n      <li>Amosin (RU);</li>\n      <li>Amotaks (PL);</li>\n      <li>Amoval (PE, PY);</li>\n      <li>Amox (IT);</li>\n      <li>Amoxa (SG);</li>\n      <li>Amoxal (CO, VE);</li>\n      <li>Amoxapen (ET, HK, MT);</li>\n      <li>Amoxar (DK);</li>\n      <li>Amoxcillin (TH);</li>\n      <li>Amoxen (ZW);</li>\n      <li>Amoxi-SAAR (DE);</li>\n      <li>Amoxibay (CO);</li>\n      <li>Amoxibel (JO);</li>\n      <li>Amoxibeta (DE);</li>\n      <li>Amoxicap (HK, PK, ZA);</li>\n      <li>Amoxicilina (CO, EC);</li>\n      <li>Amoxiclin (PE);</li>\n      <li>Amoxidal (AR, UY);</li>\n      <li>Amoxidin (AE);</li>\n      <li>Amoxidin 7 (PE);</li>\n      <li>Amoxidrex (LB);</li>\n      <li>Amoxifur (MX);</li>\n      <li>Amoxiga (CO, VE);</li>\n      <li>Amoxigran (HK);</li>\n      <li>Amoxil (AE, AU, BR, EC, EG, ET, GB, GR, ID, IE, JO, KW, LB, LT, MT, MX, NZ, PE, PT, QA, SA, ZA);</li>\n      <li>Amoxilan (AT, VE);</li>\n      <li>Amoxilin (CN);</li>\n      <li>Amoximex (LB);</li>\n      <li>Amoxin (FI, IS);</li>\n      <li>Amoxipen (AE, PE, VN);</li>\n      <li>Amoxipenil (CL);</li>\n      <li>Amoxisol (MX);</li>\n      <li>Amoxistad (AT);</li>\n      <li>Amoxitab (HK);</li>\n      <li>Amoxivan (IN);</li>\n      <li>Amoxivet (MX);</li>\n      <li>Amoxsan (ID);</li>\n      <li>Amoxy (CN);</li>\n      <li>Amoxy Care (IL);</li>\n      <li>Amoxydar (AE, JO, QA, SA);</li>\n      <li>Amoxypen (BE);</li>\n      <li>Ampin (PK);</li>\n      <li>Amyn (LK);</li>\n      <li>Anamox (PY);</li>\n      <li>Apimox (BD);</li>\n      <li>Aproxal (GR, JO);</li>\n      <li>Aroxin (SG);</li>\n      <li>Atak (BR);</li>\n      <li>Atoksilin (TR);</li>\n      <li>Avlomox (BD);</li>\n      <li>Bactimed (BE);</li>\n      <li>Bactox (LV);</li>\n      <li>Bactox Ge (FR);</li>\n      <li>Balmox (ZW);</li>\n      <li>Beamoxy (MY);</li>\n      <li>Betamox (MY);</li>\n      <li>Betmox (IN);</li>\n      <li>Brumox (PH);</li>\n      <li>Bufamoxy (ID);</li>\n      <li>Cilamox (AU);</li>\n      <li>Cipamox (PK, PT);</li>\n      <li>Clamoxyl (BE, CH, ES, FR, LU, PT);</li>\n      <li>Clonamox (HU, IE);</li>\n      <li>Coamox (TH);</li>\n      <li>Danoxilin (ID);</li>\n      <li>Devamox (TR);</li>\n      <li>Dimopen (MX);</li>\n      <li>Duomox (BG, CZ, HU, PL, RO);</li>\n      <li>Duzimicin (BR);</li>\n      <li>Dymoxin (TH);</li>\n      <li>E-Mox (AE, ET, QA, SA);</li>\n      <li>Ecobol (RU);</li>\n      <li>Edamox (HK);</li>\n      <li>Elmox (PK);</li>\n      <li>Ethimox (ID);</li>\n      <li>Fabamox (PY, UY);</li>\n      <li>Farconcil (EG);</li>\n      <li>Fisamox (AU);</li>\n      <li>Flemoksyn (UA);</li>\n      <li>Flemoxin (AE, BE, DK, EG, KW, NL, PT, QA, RU);</li>\n      <li>Foxolin (KR);</li>\n      <li>Geramox (IE);</li>\n      <li>Gexcil (PH);</li>\n      <li>Gimalxina (MX);</li>\n      <li>Glomox (AE, LB, QA, SA);</li>\n      <li>Gramox (RU);</li>\n      <li>Grinsul (AR);</li>\n      <li>Grunamox (EC);</li>\n      <li>Hiconcil (LT, LV, PL, VN);</li>\n      <li>Hikontsyl (UA);</li>\n      <li>Hymox (AE, JO, KW, QA, SA);</li>\n      <li>Hypher (CN);</li>\n      <li>Ibiamox (EG, NZ, TH);</li>\n      <li>Ikamoxyl (ID);</li>\n      <li>Imacillin (DK, NO, SE);</li>\n      <li>Imadrax (DK);</li>\n      <li>Imox (ET, ZW);</li>\n      <li>InfectoMox (DE);</li>\n      <li>J Mox (BD);</li>\n      <li>Julphamox (AE, JO, KW, LB, QA, SA);</li>\n      <li>Jutamox (DE);</li>\n      <li>Kemox (IN);</li>\n      <li>Kymoxin (KR);</li>\n      <li>Lamoxy (IN);</li>\n      <li>Largopen (ET);</li>\n      <li>Linmox (VE);</li>\n      <li>Loxyl (BD);</li>\n      <li>Magnimox (PE);</li>\n      <li>Manmox (TH);</li>\n      <li>Max (IN);</li>\n      <li>Maxamox (AU);</li>\n      <li>Medomox (ZW);</li>\n      <li>Meixil (TH);</li>\n      <li>Mexylin (ID);</li>\n      <li>Miloxy (ZW);</li>\n      <li>Mopen (IT);</li>\n      <li>Morgenxil (ES);</li>\n      <li>Mox (IN);</li>\n      <li>Moxatid (BD);</li>\n      <li>Moxi (LK);</li>\n      <li>Moxicor (LK);</li>\n      <li>Moxifar (UY);</li>\n      <li>Moxilen (HK, JO, LB, LV, MT, MY, RO, SG, VN);</li>\n      <li>Moxilin (BD);</li>\n      <li>Moxiram (JO);</li>\n      <li>Moxol (LK);</li>\n      <li>Moxtam (UY);</li>\n      <li>Moxxo (TH);</li>\n      <li>Moxylin (EC);</li>\n      <li>Moxypen (IL, ZA);</li>\n      <li>Moxyvit (IL);</li>\n      <li>Mymox (LV);</li>\n      <li>Neomox (AE, KW, SA);</li>\n      <li>Nobactam (AR);</li>\n      <li>Novamox (CL);</li>\n      <li>Novamoxin (KW);</li>\n      <li>Novax (ID);</li>\n      <li>Numoxylin (LK);</li>\n      <li>Ocylin (BR);</li>\n      <li>Opimox (ID);</li>\n      <li>Opimox Forte (ID);</li>\n      <li>Optamox (CL);</li>\n      <li>Oramox (IE);</li>\n      <li>Ospamoks (UA);</li>\n      <li>Ospamox (AE, AT, BG, CZ, EE, EG, HR, HU, ID, JO, KW, LB, LT, LV, MY, NZ, PL, PT, QA, RU, SA, SI, SK, VE);</li>\n      <li>Pamocil (IT, MT);</li>\n      <li>Pamoxin (KR);</li>\n      <li>Pasetocin (JP);</li>\n      <li>Penamox (AE, ET, JO, KW, LB, QA, SA);</li>\n      <li>Penbiosyn (PH);</li>\n      <li>Pinamox (IE);</li>\n      <li>Pondnoxcill (TH);</li>\n      <li>Pyramox (TH);</li>\n      <li>Ranmoxy (AU, NZ, ZA);</li>\n      <li>Ranoxyl (AE, TH, ZW);</li>\n      <li>Remox (SA);</li>\n      <li>Remoxil (TR);</li>\n      <li>Ri Ao (CN);</li>\n      <li>Rivamox (ET);</li>\n      <li>Sanet (PY);</li>\n      <li>Sapox (BD);</li>\n      <li>Sawacillin (JP);</li>\n      <li>Sia-mox (TH);</li>\n      <li>Sinot (UY);</li>\n      <li>Sintopen (IT);</li>\n      <li>Solpenox (ID);</li>\n      <li>Strimox (SG, ZW);</li>\n      <li>Taimox (PH);</li>\n      <li>Telmox (AR);</li>\n      <li>Teramoxyl (PH);</li>\n      <li>Trifamox (AR);</li>\n      <li>Trimoxal (VE);</li>\n      <li>Ultramox (JO, KW);</li>\n      <li>Unimox (SG);</li>\n      <li>Velamox (BR, PE);</li>\n      <li>Widecillin (ID, JP);</li>\n      <li>Winpen (LV);</li>\n      <li>Yomax (ZA);</li>\n      <li>Zai Lin (CN);</li>\n      <li>Zeemox (PK);</li>\n      <li>Zerrsox (PH);</li>\n      <li>Zimox (IT);</li>\n      <li>Zymoxyl (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book</i>: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media, &ldquo;Diagnosis and Management of Acute Otitis Media,&rdquo; <i>Pediatrics</i>, 2004, 113(5):1451-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/15121972/pubmed\" target=\"_blank\" id=\"15121972\">15121972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol.</i> 2011;117(6):1472-1483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/21606770/pubmed\" target=\"_blank\" id=\"21606770\">21606770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12892448\"></a>American Dental Association (ADA); American Academy of Orthopedic Surgeons (AAOS). Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc. 2003;134(7):895-899.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/12892448/pubmed\" target=\"_blank\" id=\"12892448\">12892448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amoxicillin [prescribing information]. North Wales, PA: Teva Pharmaceuticals; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amoxil (amoxicillin) [prescribing information]. Bristol, TN: Dr Reddy&rsquo;s Laboratories; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andrew MA, Easterling TR, Carr DB, et al. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. <i>Clin Pharmacol Ther.</i> 2007;81(4):547-556.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/17329990/pubmed\" target=\"_blank\" id=\"17329990\">17329990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 61, 153.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Belarmino JM and Kogan BA. Management of neonatal hydronephrosis. <i>Early Hum Dev.</i> 2006;82(1):9-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/16427220/pubmed\" target=\"_blank\" id=\"16427220\">16427220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benyamini L, Merlob P, Stahl B, et al, &quot;The Safety of Amoxicillin/Clavulanic Acid and Cefuroxime During Lactation,&quot; <i>Ther Drug Monit</i>, 2005, 27(4):499-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/16044108/pubmed\" target=\"_blank\" id=\"16044108\">16044108</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boguniewicz M and Leung DY, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(3):221-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/7761188/pubmed\" target=\"_blank\" id=\"7761188\">7761188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, &ldquo;Management of Community-Acquired Pediatric Pneumonia in an Era of Increasing Antibiotic Resistance and Conjugate Vaccines,&rdquo; <i>Pediatr Infect Dis J</i>, 2002, 21:592-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/12182396/pubmed\" target=\"_blank\" id=\"12182396\">12182396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 20th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 21st ed. American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24777226\"></a>Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-e1436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/24777226/pubmed\" target=\"_blank\" id=\"24777226\">24777226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canafax DM, Yuan Z, Chonmaitree T, et al, &ldquo;Amoxicillin Middle Ear Fluid Penetration and Pharmacokinetics in Children With Acute Otitis Media,&rdquo; <i>Pediatr Infect Dis J</i>, 1998, 17(2):149-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/9493813/pubmed\" target=\"_blank\" id=\"9493813\">9493813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Sexually Transmitted Diseases Treatment Guidelines, 2015,&quot; <i>MMWR Recomm Rep</i>, 2015, 64(RR-3):1-140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/21160459/pubmed\" target=\"_blank\" id=\"21160459\">21160459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Use of Anthrax Vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices,&rdquo; <i>MMWR Recomm Rep</i>, 2010, 59(RR-6):1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/20651644/pubmed\" target=\"_blank\" id=\"20651644\">20651644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/28071659/pubmed\" target=\"_blank\" id=\"28071659\">28071659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2007;102(8):1808-1825. doi: 10.1111/j.1572-0241.2007.01393.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow MS, Quintiliani R, and Nightingale CH, &ldquo;<i>In Vivo</i> Inactivation of Tobramycin by Ticarcillin. A Case Report,&rdquo; <i>JAMA</i>, 1982, 247(5):658-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/6798229/pubmed\" target=\"_blank\" id=\"6798229\">6798229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dajani AS, Taubert KA, Wilson WW, et al, &ldquo;Prevention of Bacterial Endocarditis. Recommendations by the American Heart Association,&rdquo; <i>JAMA</i>, 1997, 277(22):1794-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/9178793/pubmed\" target=\"_blank\" id=\"9178793\">9178793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daly JS, Dodge RA, Glew RH, et al, &ldquo;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,&quot; <i>J Perinatol</i>, 1997, 17(1):42-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/9069064/pubmed\" target=\"_blank\" id=\"9069064\">9069064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dougall HT, Smith L, Duncan C, et al, &ldquo;The Effect of Amoxicillin on Salivary Nitrite Concentrations: An Important Mechanism of Adverse Reactions?&rdquo; <i>Br J Clin Pharmacol</i>, 1995, 39(4):460-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/7640157/pubmed\" target=\"_blank\" id=\"7640157\">7640157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell JA, Korth-Bradley J, Milisci M, et al, &ldquo;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&rdquo; <i>J Clin Pharmacol</i>, 2001, 41:979-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/11549103/pubmed\" target=\"_blank\" id=\"11549103\">11549103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/27102658/pubmed\" target=\"_blank\" id=\"27102658\">27102658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farchione LA, &ldquo;Inactivation of Aminoglycosides by Penicillins,&rdquo; <i>J Antimicrob Chemother</i>, 1982, 8(Suppl A):27-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/7263563/pubmed\" target=\"_blank\" id=\"7263563\">7263563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs PC, Stickel S, Anderson PH, et al, &ldquo;<i>In Vitro</i> Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,&rdquo; <i>Antimicrob Agents Chemother</i>, 1991, 35(1):182-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/2014975/pubmed\" target=\"_blank\" id=\"2014975\">2014975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. <i>Circulation</i>. 2009;119(11):1541-1551. doi: 10.1161/CIRCULATIONAHA.109.191959.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/19246689/pubmed\" target=\"_blank\" id=\"19246689\">19246689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein LH, Berlin M, Tsur L, Bortnik O, Binyamini L, Berkovitch M. The safety of macrolides during lactation. <i>Breastfeed Med</i>. 2009;4(4):197-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/19366316/pubmed\" target=\"_blank\" id=\"19366316\">19366316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenbaum LA and Mesrobian HG. Vesicoureteral reflux. <i>Pediatr Clin North Am.</i> 2006;53(3):413-427.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/16716788/pubmed\" target=\"_blank\" id=\"16716788\">16716788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17522387\"></a>Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2007;69(1):91-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/17522387/pubmed\" target=\"_blank\" id=\"17522387\">17522387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halstenson CE, Wong MO, Herman CS, et al, &ldquo;Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,&rdquo; <i>Antimicrob Agents Chemother</i>, 1992, 36(9):1832-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/1416875/pubmed\" target=\"_blank\" id=\"1416875\">1416875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hautekeete ML, Brenard R, Horsmans Y, et al, &ldquo;Liver Injury Related to Amoxycillin-Clavulanic Acid: Interlobular Bile-Duct Lesions and Extrahepatic Manifestations,&rdquo; <i>J Hepatol</i>, 1995, 22(1):71-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/7751590/pubmed\" target=\"_blank\" id=\"7751590\">7751590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24447897\"></a>Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect Dis</i>. 2014;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/24447897/pubmed\" target=\"_blank\" id=\"24447897\">24447897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. September 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed October 8, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill S, Yeates M, Pathy J, et al, &ldquo;A Controlled Trial of Norfloxacin and Amoxicillin in the Treatment of Uncomplicated Urinary Tract Infection in the Elderly,&rdquo; <i>J Antimicrob Chemother</i>, 1985, 15(4):505-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/3159711/pubmed\" target=\"_blank\" id=\"3159711\">3159711</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hitt CM, Patel KB, Nicolau DP, et al, &ldquo;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&rdquo; <i>Am J Health Syst Pharm</i>, 1997, 54(23):2704-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/9408514/pubmed\" target=\"_blank\" id=\"9408514\">9408514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, et al, &quot;Prospective Follow-Up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication,&quot; <i>Am J Obstet Gynecol</i>, 1993, 168(5):1393-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jevsevar DS and Abt E, &quot;The New AAOS-ADA Clinical Practice Guideline on Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures,&quot; <i>J Am Acad Orthop Surg</i>, 2013, 21(3):195-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/23457071/pubmed\" target=\"_blank\" id=\"23457071\">23457071</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones KH and Hill SA, &ldquo;The Toxicology, Absorption and Pharmacokinetics of Amoxicillin,&rdquo; <i>Adv Clin Pharmacol</i>, 1974, 7:20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/4619748/pubmed\" target=\"_blank\" id=\"4619748\">4619748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. <i>Acta Paediatr Scand.</i> 1981;70(3):285-288.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/7246123/pubmed\" target=\"_blank\" id=\"7246123\">7246123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for <i>Helicobacter pylori</i> infection in children. <i>J Pediatr Gastroenterol Nutr</i>. 2011;53(2):230-243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/21558964/pubmed\" target=\"_blank\" id=\"21558964\">21558964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konishi H, Goto M, Nakamoto Y, et al, &ldquo;Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,&rdquo; <i>Antimicrob Agents Chemother</i>, 1983, 23(5):653-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/6223576/pubmed\" target=\"_blank\" id=\"6223576\">6223576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Korppi M, &ldquo;Community-Acquired Pneumonia in Children. Issues in Optimizing Antibacterial Treatment,&rdquo; <i>Pediatr Drugs</i>, 2003, 5(12):821-32.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau A, Lee M, Flascha S, et al, &ldquo;Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients With Normal Renal Function,&rdquo; <i>Antimicrob Agents Chemother</i>, 1983, 24(4):533-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/6651279/pubmed\" target=\"_blank\" id=\"6651279\">6651279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2013;131(3):e964-e999. doi: 10.1542/peds.2012-3488.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin KJ, Mitchell AA, Yau WP, Louik C, Hernandez-Diaz S. Maternal exposure to amoxicillin and the risk of oral clefts. <i>Epidemiology.</i> 2012;23(5):699-705.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/22766750/pubmed\" target=\"_blank\" id=\"22766750\">22766750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the managementof community-acquired pneumonia in adults. <i>Clin Infect Dis</i>. 2007;44(suppl 2):S27-S72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mattoo TK. Medical management of vesicoureteral reflux - quiz within the article. Don't overlook placebos. <i>Pediatr Nephrol.</i> 2007;22(8):1113-1120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/17483966/pubmed\" target=\"_blank\" id=\"17483966\">17483966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McIntosh K, &ldquo;Community-Acquired Pneumonia in Children,&rdquo; <i>N Engl J Med</i>, 2002, 346(6):429-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/11832532/pubmed\" target=\"_blank\" id=\"11832532\">11832532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/24457117/pubmed\" target=\"_blank\" id=\"24457117\">24457117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi: 10.1038/ajg.2017.154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/28631728/pubmed\" target=\"_blank\" id=\"28631728\">28631728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moxatag (amoxicillin) [prescribing information]. Locust Valley, NY: Fera Pharmaceuticals LLC; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muller AE, Oostvogel PM, DeJongh J, et al. Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera. <i>Antimicrob Agents Chemother.</i> 2009;53(4):1574-1580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/19164154/pubmed\" target=\"_blank\" id=\"19164154\">19164154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Novamoxin (amoxicillin) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-2492.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oe PL, Simonian S, Verhoef J, &ldquo;Pharmacokinetics of the New Penicillins, Amoxicillin and Flucloxacillin in Patients With Terminal Renal Failure Undergoing Hemodialysis,&rdquo; <i>Chemotherapy</i>, 1973, 19:279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/4787741/pubmed\" target=\"_blank\" id=\"4787741\">4787741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parry MF, &ldquo;The Penicillins,&rdquo; <i>Med Clin North Am</i>, 1987, 71(6):1093-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/3320613/pubmed\" target=\"_blank\" id=\"3320613\">3320613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prignet JM, Galzin M, Duval JL, et al, &ldquo;Amoxicillin-Induced Esophageal Ulcer With Intractable Hiccups as the Presenting Manifestation,&rdquo; <i>Sem Hop</i>, 1995, 71:186-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Puh&oacute; EH, Szunyogh M, M&eacute;tneki J, Czeizel AE. Drug treatment during pregnancy and isolated orofacial clefts in hungary. <i>Cleft Palate Craniofac J.</i> 2007;44(2):194-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/17328645/pubmed\" target=\"_blank\" id=\"17328645\">17328645</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2 suppl):S1-S39. doi: 10.1177/0194599815572097.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/25832968/pubmed\" target=\"_blank\" id=\"25832968\">25832968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russoe ME and Atkins-Thor E, &ldquo;Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,&rdquo; <i>Clin Nephrol</i>, 1981, 15(4):175-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/7237864/pubmed\" target=\"_blank\" id=\"7237864\">7237864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. <i>J Antimicrob Chemother</i>. 1991;27(4):405-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/1856121/pubmed\" target=\"_blank\" id=\"1856121\">1856121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2012, 55(10):e86-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. <i>J Am Dent Assoc.</i> 2015; 146(1):11-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/25569493/pubmed\" target=\"_blank\" id=\"25569493\">25569493</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24973422\"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi: 10.1093/cid/ciu444.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Swanson-Biearman B, Dean DS, Lopez G, et al, &ldquo;The Effects of Penicillin and Cephalosporin Ingestions in Children Less Than Six Years of Age,&rdquo; <i>Vet Hum Toxicol</i>, 1988, 30(1):66-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/3354190/pubmed\" target=\"_blank\" id=\"3354190\">3354190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo; <i>Am J Gastroenterol</i>, 2005, 100(10):2324-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/16181387/pubmed\" target=\"_blank\" id=\"16181387\">16181387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson MIB, Russo ME, Saxon BJ, et al, &ldquo;Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,&rdquo; <i>Antimicrob Agents Chemother</i>, 1982, 21(2):268-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/6462107/pubmed\" target=\"_blank\" id=\"6462107\">6462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tu YH, Stiles ML, Allen LV Jr, et al, &quot;Stability of Amoxicillin Trihydrate-Potassium Clavulanate in Original Containers and Unit Dose Oral Syringes,&quot; <i>Am J Hosp Pharm</i>, 1988, 45(5):1092-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/3400652 /pubmed\" target=\"_blank\" id=\"3400652 \">3400652 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Food and Drug Administration, Center for Drug Evaluation and Research, &ldquo;Commentary on Nonlabeled Dosing of Oral Amoxicillin in Adults and Pediatrics for Post-Exposure Inhalational Anthrax,&rdquo; December 10, 2001. Available at <a href=\"http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072106.htm\" target=\"_blank\">http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072106.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varela VM, Heller D, Silva-Senem MX, et al, &quot;Systemic Antimicrobials Adjunctive to a Repeated Mechanical and Antiseptic Therapy for Aggressive Periodontitis: A 6-Month Randomized Controlled Trial,&quot; <i>J Periodontol</i>, 2011, 82(8):1121-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/21235333/pubmed\" target=\"_blank\" id=\"21235333\">21235333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viollier AF, Standiford HC, Drusano GL, et al, &ldquo;Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,&rdquo; <i>J Antimicrob Chemother</i>, 1985, 15(5):597-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/4008387/pubmed\" target=\"_blank\" id=\"4008387\">4008387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. <i>Pediatrics</i>. 2013;132(1):e262-e280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/23796742/pubmed\" target=\"_blank\" id=\"23796742\">23796742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walterspiel JN, Feldman S, Van R, et al, &ldquo;Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,&rdquo; <i>Antimicrob Agents Chemother</i>, 1991, 35(9):1875-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/1952861/pubmed\" target=\"_blank\" id=\"1952861\">1952861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.<i> Perit Dial Int</i>. 2012;32(Suppl 2):S32-S86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Westphal JF, Jehl F, Brogard JM, et al, &ldquo;Amoxicillin Intestinal Absorption Reduction by Amiloride: Possible Role of the Na<sup>+</sup>-H<sup>+</sup> Exchanger,&rdquo; <i>Clin Pharmacol Ther</i>, 1995, 57(3):257-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/7697943/pubmed\" target=\"_blank\" id=\"7697943\">7697943</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; <i>Circulation</i>, 2007, 115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &quot;Mastitis: Causes and Management, Publication Number WHO/FCH/CAH/00.13,&quot; World Health Organization: Geneva, 2000.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2006;43(9):1089-1134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wright AJ, &ldquo;The Penicillins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/10090000/pubmed\" target=\"_blank\" id=\"10090000\">10090000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Amoxicillin Update,&rdquo; <i>Gen Dent</i>, 1991, 39(5):322,4,6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-drug-information/abstract-text/1812049/pubmed\" target=\"_blank\" id=\"1812049\">1812049</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8673 Version 266.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F134511\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134512\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F134562\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F134516\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F134538\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F134517\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F134518\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673165\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F134488\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F134472\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50665095\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F134492\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F134491\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475041\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134569\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134479\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134495\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134476\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298741\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134481\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134484\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5720643\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5695240\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F134498\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F134486\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134475\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F134494\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F134497\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F134499\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8673|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amoxicillin-patient-drug-information\" class=\"drug drug_patient\">Amoxicillin: Patient drug information</a></li><li><a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">Amoxicillin: Pediatric drug information</a></li></ul></div></div>","javascript":null}